文献速递肝病

FIB-4肝纤维化分期可预测HIV感染与未感染患者新发心力衰竭

FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients.
PubMed 文献 · Hepatology · 2017-08-30

在退伍军人老龄化队列研究中,96,373名无现患心血管疾病的参与者随访6.9年,发生3,844例新发充血性心力衰竭。FIB-4 1.45–3.25(中度纤维化)和FIB-4>3.25(晚期纤维化/肝硬化)均与新发充血性心力衰竭相关,HR分别为1.17(95%CI 1.07–1.27)和1.65(95%CI 1.43–1.92),晚期纤维化/肝硬化的关联不受HIV/HCV感染状态影响。

要点

  • FIB-4 1.45–3.25(中度纤维化)与新发充血性心力衰竭相关,HR 1.17(95%CI 1.07–1.27)。
  • FIB-4>3.25(晚期纤维化/肝硬化)与新发充血性心力衰竭相关,HR 1.65(95%CI 1.43–1.92)。
  • 晚期纤维化/肝硬化与新发充血性心力衰竭的关联在无HCV和/或HIV感染者中依然存在。

核心结论

  • 中度及晚期肝纤维化/肝硬化与新发充血性心力衰竭风险升高相关。
  • 晚期纤维化/肝硬化与新发充血性心力衰竭的关联即使在无丙型肝炎和/或HIV感染的参与者中依然存在。
  • 评估肝脏健康可能对降低未来充血性心力衰竭事件风险具有重要意义,尤其在心血管疾病风险升高且肝病常见的HIV和丙型肝炎感染者中。

研究设计与样本

  • 退伍军人老龄化队列研究(Veterans Aging Cohort Study),纳入2003年4月1日及以后存活且无现患心血管疾病的参与者。
  • 随访至首次充血性心力衰竭事件、死亡、末次随访日期或2011年12月31日。
  • 肝纤维化采用FIB-4指数评估,该指数基于年龄、转氨酶和血小板计算。
  • 采用Cox比例风险回归模型,并校正心血管疾病危险因素。
  • 共纳入96,373名参与者,随访6.9年。

主要发现

  • 随访期间共发生3,844例新发充血性心力衰竭事件。
  • FIB-4 1.45–3.25(中度纤维化)与新发充血性心力衰竭相关,HR 1.17(95%CI 1.07–1.27)。
  • FIB-4>3.25(晚期纤维化/肝硬化)与新发充血性心力衰竭相关,HR 1.65(95%CI 1.43–1.92)。
  • 晚期纤维化/肝硬化与新发充血性心力衰竭的关联不受HIV/HCV感染状态影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Liver fibrosis is common, particularly in individuals who are infected with human immunodeficiency virus (HIV). HIV-infected individuals have excess congestive heart failure (CHF) risk compared with uninfected people. It remains unknown whether liver fibrosis stage influences the CHF risk or if HIV or hepatitis C virus (HCV) infection modifies this association. Our objectives were to assess whether 1) stage of liver fibrosis is independently associated with incident CHF and 2) the association between stage of liver fibrosis and incident CHF is modified by HIV/HCV status. Participants alive on or after April 1, 2003, in the Veterans Aging Cohort Study were included. Those without prevalent cardiovascular disease were followed until their first CHF event, death, last follow-up date, or December 31, 2011. Liver fibrosis was measured using the fibrosis 4 index (FIB-4), which is calculated using age, aminotransferases, and platelets. Cox proportional hazards regression models were adjusted for cardiovascular disease risk factors. Among 96,373 participants over 6.9 years, 3844 incident CHF events occurred. FIB-4 between 1.45 and 3.25 (moderate fibrosis) and FIB-4 > 3.25 (advanced fibrosis/cirrhosis) were associated with CHF (hazard ratio [95% confidence interval], 1.17 [1.07-1.27] and 1.65 [1.43-1.92], respectively). The association of advanced fibrosis/cirrhosis and incident CHF persisted regardless of HIV/HCV status. CONCLUSION: Moderate and advanced liver fibrosis/cirrhosis are associated with an increased risk of CHF. The association for advanced fibrosis/cirrhosis persists even among participants without hepatitis C and/or HIV infection. Assessing liver health may be important for reducing the risk of future CHF events, particularly among HIV and hepatitis C infected people among whom cardiovascular disease risk is elevated and liver disease is common. (Hepatology 2017;66:1286-1295).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. So-Armah KA, Lim JK, Lo Re V, et al. FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients. Hepatology. 2017. PMID: 28543215. doi:10.1002/hep.29285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。